[1]李 瑛,李 军.多发性骨髓瘤患者血清中IL-6与IL-27水平监测的临床应用[J].现代检验医学杂志,2016,31(04):87-89.[doi:10.3969/j.issn.16717-414.2016.04.023]
　LI Ying,LI Jun.Clinical Application of Monitoring IL-6 and IL-27 Levels in Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2016,31(04):87-89.[doi:10.3969/j.issn.16717-414.2016.04.023]
点击复制

多发性骨髓瘤患者血清中IL-6与IL-27水平监测的临床应用()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第31卷
期数:
2016年04期
页码:
87-89
栏目:
论著
出版日期:
2016-08-10

文章信息/Info

Title:
Clinical Application of Monitoring IL-6 and IL-27 Levels in Patients with Multiple Myeloma
文章编号:
1671-7414(2016)04-087-03
作者:
李 瑛; 李 军
陕西中医药大学附属医院检验科,陕西咸阳 712000
Author(s):
LI Ying; LI Jun
Department of Clinical Laboratory,Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine,Shaanxi Xianyang 712000,China
关键词:
多发性骨髓瘤;  白介素-6;  白介素-27;  临床应用
分类号:
R733.3; R730.43
DOI:
10.3969/j.issn.16717-414.2016.04.023
文献标志码:
A
摘要:
目的 通过检测多发性骨髓瘤(multiple myeloma,MM)患者血清中IL-6与IL-27表达水平,探讨其在MM病情进展程度及疗效评价中的意义。方法 按照修订的R-ISS国际预后分期诊断标准,选择MM患者52例,其中Ⅰ期16例,Ⅱ期18例,Ⅲ期18例,选择同期正常对照组20例。用ELISA法检测各组血清中IL-6与IL-27表达水平,并随访观察其预后。结果 Ⅰ期、Ⅱ期与Ⅲ期MM患者血清中IL-6表达水平均明显高于对照组,且差异有统计学意义(t=4.012,5.134,6.161,均P<0.01),Ⅲ期血清中IL-6的表达水平高于Ⅰ期,且差异有统计学意义(t=2.132,P<0.05)。而Ⅲ期IL-27表达水平显著低于对照组,且差异有统计学意义(t=3.831,P<0.01),Ⅰ期、Ⅱ期血清中IL-27表达水平也低于对照组,且差异有统计学意义(t=2.012,2.198,均P<0.05)。MM患者血清中IL-6表达水平与IL-27表达水平为负相关关系(r=-0.510,P<0.05)。MM患者初治组与复发组血清中IL-6的表达水平均明显高于对照组,且差异有统计学意义(t=4.331,5.221,均P<0.01),而缓解组IL-6表达水平显著低于初治组,且差异有统计学意义(t=4.101,P<0.01)。初治组与复发组血清中IL-27的表达水平均明显低于对照组,且差异有统计学意义(t=2.133,2.521,均P<0.05),而缓解组IL-6表达水平高于初治组,且差异有统计学意义(t=2.001,P<0.05)。结论 多发性骨髓瘤的病情进展与患者血清中IL-6升高或IL-27降低有关,检测相关细胞因子IL-6和IL-27水平变化有助于判断病情严重程度及评估预后。
Abstract:
Objective Through the detection of IL-6 and IL-27 expression levels in sera of patients with multiple myeloma,to explore its significance of judging the extent of serious condition and treatment of multiple myeloma.Methods According to the revision of the R-ISS international prognostic staging diagnosis standards,selected 52 patients with multiple myeloma,Ⅰ period of 16 cases,Ⅱ period 18 cases,Ⅲ period 18 cases,and 20 cases at same time as for as normal control group.Detected serum IL-6 and IL-27 expression levels in each group with ELISA method,and the prognosis wasfollowed up and observed.Results Serum IL-6 expression levels in Ⅰ,Ⅱ and Ⅲ stage of patients with MM were significantly higher than that of control group,and the difference was statistically significant(t=4.012,5.134,6.161,P<0.01).In Ⅲ period,the expression levelof IL-6 in serum was higher than Ⅰ period,and the difference was statistically significant(t=2.132,P<0.05).And in Ⅲ period,IL-27 expression level was significantly lower than the control group,and the difference was statistically significant(t=3.831,P<0.01).In Ⅰ,Ⅱ stage,serum IL-27expression level was lower than the control group,and the difference was statistically significant(t=2.012,2.198,P<0.05).Serum IL-6 and IL-27expression levels in patients with MM were negative correlation(r=0.510,P<0.05).Serum IL-6 expression levels in first-treated group and recurrence group of patients with MM were significantly higher than that of control group,and the difference was statistically significant(t=4.331,5.221,P<0.01).While IL-6 expression level of alleviated group was significantly lowerthan in the early treated group,and the difference was statistically significant(t=4.101,P<0.01).Serum IL-27 expression levels of initial groupand recurrence group were significantly lower than the control group,and the difference was statistically significant(t=2.133,2.521,P=<0.05).Serum IL-6 expression level of alleviated group was higher than the initial group,and the difference was statistically significant(t=2.001,P<0.05).Conclusion The progression of multiple myeloma was relatedto the increasion of IL-6 or the decreasion of IL-27.Testing related cytokines IL-6 and IL-27 level changes help to determine disease severity and assessing prognosis.

参考文献/References:

[1] Kyle RA, Rajkumar SV. Multiple myeloma[J].New England Journal of Medicine,2004,351(18):1860-1873.
[2] Qin SF, Liu L. Effect and safety of CIK cell infusion on peripheral blood immune cell level in the elderly patients with multiple myeloma[J].Journalof Experimental Hematology,2016,24(2):482-486.
[3] Song XN, Yang JZ, Sun LX,et al.Expression levels of IL-27 and IL-17in multiple myeloma patients:a higher ratio of IL-27:IL-17 in bone marrow was associated with a superior progression-free survival[J].Leuk Res,2013,37(9):1094-1099.
[4] Cocco C,Giuliani N,Di Carlo E,et al.Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma[J].Clin Cancer Res,2010,16(16):4188-4197.
[5] Bhutani M,Shahid Z,Schnebelen A,et al.Cutaneous manifestations of multiple myeloma and other plasma cell proliferative disorders[J].Semin Oncol,2016,43(3):395-400.
[6] 邱 爽,孟瑞芳,蒋筱漪,等.血清免疫固定电泳、蛋白电泳、免疫球蛋白及轻链定量在诊断多发性骨髓瘤中的临床应用[J].现代检验医学杂志,2015,31(2):61-64. Qiu S,Meng RF,Jiang XY,et al.Clinical application of immunofixtion electrophoresis,serum protein electrophoresis and immunoglobulins and light chain quantitative analysis in the diagnosis of multiple myeloma[J].J Mod Lab Med,2015,31(2):61-64.
[7] Smirnova OV, Manchuk VT, Agilova YN.Clinical and immunological features of infectious complications in patients with multiple myeloma[J].Vestn RossAkad Med Nauk,2015,10(5):534-540.
[8] Braga WM,Atanackovic D,Colleoni GW.The role of regulatory T cells andTh17 cells in multiple myeloma[J].Clin Dev Immunol,2012,2012(1):125-130.
[9] Lǒffler D,Brocke-Heidrich K,Pfeifer G,et al.Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction ofmicro RNA-21 through a highly conserved enhancer[J].Blood,2007,110(4):1330-1333.
[10] Obinata H,Hla T.Sphingosine-1-phosphate in coagulation and inflammation[J].Semin Immunopathol,2012,34(1):73-91.
[11] Li Y, Li D, Yan Z,et al.Potential relationship and clinical significance of miRNAs and Th17 related cytokines in patients with multiple myeloma[J].Chinese Journal of Hematology,2015,36(2):125-130.
[12] Wojno ED,Hunter CA.New directions in the basic and translational biology of interleukin-27[J].Trends Immunol,2012,33(2):91-97.
[13] Song XN,Yang JZ,Sun LX,et al.Expression levels of IL-27 and IL-17in multiple myeloma patients:a higher ratio of IL-27:IL-17 in bone marrow was associated with a superior progression-free survival[J].Leuk Res,2013,37(9):1094-1099.

相似文献/References:

[1]韩秀蕊,杨娣娣,李艳春,等.多发性骨髓瘤患者骨髓涂片与骨髓活检同步检查的比较分析[J].现代检验医学杂志,2015,30(03):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
　HAN Xiu-rui,YANG Di-di,LI Yan-chun,et al.Comparative Analysis of Bone Marrow Smears and Biopsies Synchronous Check for Myeloma Patients[J].Journal of Modern Laboratory Medicine,2015,30(04):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
[2]李 垚,杨 平.早发冠心病触珠蛋白水平及其在免疫调节中的作用研究[J].现代检验医学杂志,2015,30(01):98.[doi:10.3969/j.issn.1671-7414.2015.01.027]
　LI Yao,YANG Ping.Role of Haptoglobin in the Immunomodulatory in Patients with Premature Coronary Heart Disease[J].Journal of Modern Laboratory Medicine,2015,30(04):98.[doi:10.3969/j.issn.1671-7414.2015.01.027]
[3]邱 爽,孟瑞芳,蒋筱漪,等.血清免疫固定电泳、蛋白电泳、免疫球蛋白及轻链定量在诊断多发性骨髓瘤中的临床应用[J].现代检验医学杂志,2015,30(02):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
　QIU Shuang,MENG Rui-fang,JIANG Xiao-yi,et al.Clinical Application of Immunofixtion Electrophoresis, Serum Protein Electrophoresis and Immunoglobulins and Light Chain Quantitative Analysis in the Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2015,30(04):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
[4]郭进京,胡林辉,陶千山,等.红细胞分布宽度在多发性骨髓瘤患者预后分期中的价值[J].现代检验医学杂志,2017,32(03):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
　GUO Jin-jing,HU Lin-hui,TAO Qian-shan,et al.Value of Red Cell Distribution Width in the Prognosis of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(04):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
[5]谭 奎,沈婵娟,张 玲,等.多发性骨髓瘤患者骨髓CD269和CD317基因的差异性表达研究[J].现代检验医学杂志,2017,32(06):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　TAN Kui,SHEN Chan-juan,ZHANG Ling,et al.Differential Expression of CD269 and CD317 Genes in Bone Marrow of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(04):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[6]盘国雄,谭才燕,何嘉颖,等.多发性骨髓瘤患者血清中lncRNA PCAT-1的表达水平与临床预后研究[J].现代检验医学杂志,2018,33(01):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　PAN Guo-xiong,TAN Cai-yan,HE Jia-ying,et al.Serum LncRNA PCAT-1 Expression Level of Patients with Multiple Myeloma and Clinical Value[J].Journal of Modern Laboratory Medicine,2018,33(04):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[7]刘玉霞,胡国瑜,袁朝晖,等.CD269和CD317在多发性骨髓瘤中的表达及临床意义[J].现代检验医学杂志,2018,33(02):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LIU Yu-xia,HU Guo-yu,YUAN Chao-hui,et al.Expression of CD269 and CD317 in Multiple Myeloma and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(04):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[8]李腾达,刘 鹏,龙曙萍,等.隐球菌脑膜炎患者外周血单个核细胞PILRα升高及意义[J].现代检验医学杂志,2018,33(03):11.[doi:10.3969/j.issn.1671-7414.2018.03.004]
　LI Teng-da,LIU Peng,LONG Shu-ping,et al.Increasing Expression of PILRα in Peripheral Blood Mononuclear Cells from Patients with Cryptococcal Meningitis and Its Significance[J].Journal of Modern Laboratory Medicine,2018,33(04):11.[doi:10.3969/j.issn.1671-7414.2018.03.004]
[9]张 蓉,李国辉,刘小五,等.初诊多发性骨髓瘤患者外周血淋巴细胞绝对值/ 单核细胞绝对值比值在预测临床预后的价值研究[J].现代检验医学杂志,2020,35(01):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
　ZHANG Rong,LI Guo-hui,LIU Xiao-wu,et al.Value of Peripheral Blood Lymphocyte Absolute Value/Monocyte Absolute Value Ratio in Predicting Clinical Prognosis of Newly Diagnosed MultipleMyeloma Patients[J].Journal of Modern Laboratory Medicine,2020,35(04):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
[10]霍 豆,秦 爽,吴永昌,等.血清总轻链与游离轻链定量检测在多发性骨髓瘤诊断中的临床价值探讨[J].现代检验医学杂志,2020,35(04):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
　HUO Dou,QIN Shuang,WU Yong-chang,et al.Clinical Value of Quantitative Detection of sTLC and sFLC in Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2020,35(04):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]

备注/Memo

备注/Memo:

作者简介:李 瑛(1962-),女,大专,主管检验师,主要从事临床医学免疫学检验工作,Tel:13909101368,E-mail:2436404068@qq.com。
更新日期/Last Update: 2016-08-10